Tazeen Ahmad
Stock Analyst at B of A Securities
(3.30)
# 1,003
Out of 4,937 analysts
202
Total ratings
47.85%
Success rate
1.61%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $126 → $134 | $111.66 | +20.01% | 9 | Aug 5, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $68 → $84 | $45.38 | +85.10% | 18 | Jul 29, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Underperform | $20 → $10 | $18.23 | -45.15% | 24 | Jul 23, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $23 → $24 | $24.38 | -1.54% | 8 | Jul 16, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $336 → $359 | $438.93 | -18.21% | 4 | Jul 11, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Buy | $8 | $2.72 | +194.12% | 1 | Jul 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $73 → $95 | $91.96 | +3.31% | 9 | Jul 10, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Buy | $13 → $15 | $8.31 | +80.51% | 12 | Jul 1, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $201 → $216 | $191.49 | +12.80% | 10 | Jun 9, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $18 → $23 | $24.60 | -6.50% | 15 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $7.69 | -47.98% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $1 → $0.8 | $0.80 | -0.30% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $13.96 | +93.41% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $6.29 | +345.15% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $64.00 | +9.38% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $5.63 | +610.48% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $125.01 | +43.19% | 3 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $12.40 | +77.49% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.07 | +180.37% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $68 → $90 | $78.39 | +14.81% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.77 | +121.73% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $6.49 | -69.16% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $661.83 | -8.28% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $27.54 | +175.96% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $2.36 | +323.73% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $0.92 | +551.18% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $12.20 | +22.95% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $20.15 | -45.41% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $2.68 | -25.37% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $0.84 | +618.13% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $9.56 | +56.90% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $45.95 | +30.58% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.06 | +1,409.43% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $9.17 | +369.18% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $205.42 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $10.00 | +2,900.00% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.19 | +310.96% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $25.20 | +90.48% | 6 | Oct 10, 2018 |
BioNTech SE
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $111.66
Upside: +20.01%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $68 → $84
Current: $45.38
Upside: +85.10%
Sarepta Therapeutics
Jul 23, 2025
Downgrades: Underperform
Price Target: $20 → $10
Current: $18.23
Upside: -45.15%
Apellis Pharmaceuticals
Jul 16, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $24.38
Upside: -1.54%
Alnylam Pharmaceuticals
Jul 11, 2025
Maintains: Buy
Price Target: $336 → $359
Current: $438.93
Upside: -18.21%
Taysha Gene Therapies
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $2.72
Upside: +194.12%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $91.96
Upside: +3.31%
BioCryst Pharmaceuticals
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $8.31
Upside: +80.51%
Ascendis Pharma
Jun 9, 2025
Maintains: Buy
Price Target: $201 → $216
Current: $191.49
Upside: +12.80%
ACADIA Pharmaceuticals
Jun 5, 2025
Maintains: Neutral
Price Target: $18 → $23
Current: $24.60
Upside: -6.50%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $7.69
Upside: -47.98%
May 19, 2025
Maintains: Underperform
Price Target: $1 → $0.8
Current: $0.80
Upside: -0.30%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $13.96
Upside: +93.41%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $6.29
Upside: +345.15%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $64.00
Upside: +9.38%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $5.63
Upside: +610.48%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $125.01
Upside: +43.19%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $12.40
Upside: +77.49%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.07
Upside: +180.37%
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $78.39
Upside: +14.81%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $6.77
Upside: +121.73%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $6.49
Upside: -69.16%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $661.83
Upside: -8.28%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $27.54
Upside: +175.96%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $2.36
Upside: +323.73%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $0.92
Upside: +551.18%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $12.20
Upside: +22.95%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $20.15
Upside: -45.41%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $2.68
Upside: -25.37%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $0.84
Upside: +618.13%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $9.56
Upside: +56.90%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $45.95
Upside: +30.58%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.06
Upside: +1,409.43%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $9.17
Upside: +369.18%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $205.42
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $10.00
Upside: +2,900.00%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.19
Upside: +310.96%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $25.20
Upside: +90.48%